Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

14.14
+0.31002.24%
Post-market: 13.72-0.4160-2.94%17:05 EDT
Volume:2.83M
Turnover:40.08M
Market Cap:1.11B
PE:6.97
High:14.43
Open:13.58
Low:13.55
Close:13.83
52wk High:17.29
52wk Low:5.70
Shares:78.65M
Float Shares:70.64M
Volume Ratio:1.56
T/O Rate:4.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.03
EPS(LYR):1.87
ROE:82.56%
ROA:2.29%
PB:4.79
PE(LYR):7.56

Loading ...

AKESO (09926) Gains NMPA Nod for Third Indication of Its First-in-Class Bispecific Antibody, Ivonescimab, in Frontline Squamous NSCLC

Stock News
·
Aug 12

BTIG Reiterates Buy on PIKTOR as New PK/PD Data De-Risk Development and Support Unchanged $55 Price Target

TIPRANKS
·
Aug 11

Press Release: Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Dow Jones
·
Aug 11

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

GlobeNewswire
·
Aug 11

Press Release: Entera Announces Second Quarter 2026 Financial Results and Business Updates

Dow Jones
·
Aug 08

Press Release: Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

Dow Jones
·
Aug 07

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
Aug 07

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals

GlobeNewswire
·
Aug 06

Press Release: Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Dow Jones
·
Aug 03

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

GlobeNewswire
·
Aug 03

HENLIUS Receives NMPA Approval for Clinical Trial of HLX43 Combination Therapy in Advanced Solid Tumors

Stock News
·
Jul 31

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Completes Patient Enrollment in Phase II Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors

GlobeNewswire
·
Jul 30

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

GlobeNewswire
·
Jul 28

Agilent receives EU approval for PD-L1 IHC 22C3 pharmDx

TIPRANKS
·
Jul 23

PagerDuty price target raised to $8 from $7 at BofA

TIPRANKS
·
Jul 22

Pagerduty Cut to Underweight from Equal-weight by Morgan Stanley

Dow Jones
·
Jul 21

Morgan Stanley Downgrades PagerDuty to Underweight From Equalweight, Trims Price Target to $9 From $10

MT Newswires Live
·
Jul 21

Pagerduty, Inc. : Morgan Stanley Cuts to Underweight from Equal-weight

THOMSON REUTERS
·
Jul 21

PagerDuty downgraded to Underweight from Equal Weight at Morgan Stanley

TIPRANKS
·
Jul 21

Pagerduty Executive Chair Jennifer Tejada Sells USD 4.23 Million in Common Shares

Reuters
·
Jul 21